Oppenheimer has published a research report on Biogen Idec Inc BIIB.
In the report, Oppenheimer wrote, "BIIB has declined significantly on recent market weakness, despite no change in the company's fundamentals. We believe BG-12 will become a blockbuster oral MS therapy, based our analysis of recent data and physician feedback. We believe the drug will substantially elevate BIIB's MS franchise sales growth, despite our expectation for additional Avonex erosion."
Oppenheimer upgraded Biogen Idec from Perform to Outperform with a price target established at $109.00. Biogen Idec closed Wednesday at $90.03.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in